Laboratory of Molecular Biology, Service of Clinical Analysis, Escuela de Enfermería 7ª, Hospital Universitario La Fe, Avenida Campanar 21, Valencia, Spain.
Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.
The aim of the study is to investigate the relevance of rs1056663 and rs2708861 HUS1 polymorphisms, and rs104548, rs2981582 and rs2910164 polymorphisms of CASP8, FGFR2 and micro RNA 146A genes, respectively, as risk modifiers in hereditary breast or ovarian cancer (BC/OC) and risk factors in sporadic BC. We performed a case-control study in 189 healthy controls (CG) and 538 BC/OC cases, 340 with familial history of BC/OC (130 carriers of BRCA1/2 mutations and 210 non-carriers) and 198 sporadic BC/OC. The polymorphisms were assessed by real-time PCR using primers and fluorescent-labelled hybridization probes. We found statistically significant differences between familial BC/OC and CG for rs1056663 and rs2708861 HSU1 polymorphisms and rs2981582 FGFR2 polymorphism, particularly in non-carriers of BRCA1/2 mutations. In this group we found statistical differences for rs1056663 HSU1 and rs2981582 FGFR2 polymorphisms (p-trend < 0.006). The logistic regression confirmed that rs2981582 FGFR2 polymorphism (OR = 2.09; 95 % CI 1.35, 3.20) and the interaction between rs1056663 and rs2708861 HUS1 polymorphisms increased the risk of cancer (OR = 1.87; 95 % CI 1.19, 2.92). Furthermore, we found that the presence of rs1056663 and rs2708861 HUS1 polymorphisms is associated with early age of presentation of BC (p = 0.015) in the group of non-carriers of BRCA1/2 mutations. In addition, no association of the polymorphisms studied in sporadic BC was observed. In conclusion, the HUS1 and FGFR2 polymorphisms act as risk BC modifiers in familial BC/OC, particularly in the group of non-carriers of BRCA1/2 mutations.
本研究旨在探讨 HUS1 基因 rs1056663 和 rs2708861 多态性,以及 CASP8 基因 rs104548、rs2981582 和 rs2910164 多态性,分别作为遗传性乳腺癌或卵巢癌 (BC/OC) 的风险修饰因子和散发性 BC 的风险因素。我们在 189 名健康对照者 (CG) 和 538 名 BC/OC 病例中进行了病例对照研究,其中 340 名有 BC/OC 的家族史 (130 名携带 BRCA1/2 突变,210 名非携带者) 和 198 名散发性 BC/OC。采用实时 PCR 法用引物和荧光标记杂交探针检测多态性。我们发现,在家族性 BC/OC 与 CG 之间,rs1056663 和 rs2708861 HSU1 多态性和 rs2981582 FGFR2 多态性存在统计学差异,尤其是在 BRCA1/2 突变非携带者中。在这组患者中,我们发现 rs1056663 HSU1 和 rs2981582 FGFR2 多态性存在统计学差异 (p-trend <0.006)。逻辑回归证实,rs2981582 FGFR2 多态性 (OR=2.09;95%CI 1.35, 3.20) 和 rs1056663 与 rs2708861 HUS1 多态性之间的相互作用增加了癌症的风险 (OR=1.87;95%CI 1.19, 2.92)。此外,我们发现,rs1056663 和 rs2708861 HUS1 多态性的存在与 BRCA1/2 突变非携带者中 BC 发病年龄较早有关 (p=0.015)。此外,在散发性 BC 中未观察到研究多态性的相关性。总之,HUS1 和 FGFR2 多态性作为家族性 BC/OC 的 BC 风险修饰因子,特别是在 BRCA1/2 突变非携带者中。